Crystalline modifications of...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C544S058200

Reexamination Certificate

active

10766122

ABSTRACT:
The present invention relates to a new crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide characterized by the following X-ray diffraction pattern obtained with a CuKα, radiation at 2θ (2Theta)=4.5, 6.4, 7.5, 7.7, 8.0, 8.2, 10.0, 10.2, 10.9, 11.1, 12.9, 13.4, 14.0, 14.5, 15.1, 15.6, 16.2, 16.5, 17.3, 17.5, 18.0, 18.9, 19.3, 19.5, 19.9, 20.1, 20.6, 21.0, 21.4, 22.7, 23.1 and 23.6 and an infrared spectrum having sharp bands at 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 868, 860, 782, 705, 684 cm−1, and wherein the extrapolated melting point (DSC) is 137.2° C.

REFERENCES:
patent: 5972938 (1999-10-01), Rupniak et al.
patent: 2003/0004157 (2003-01-01), Buser et al.
patent: 1 035 115 (2000-09-01), None
patent: 2347422 (2002-09-01), None
patent: WO 95/16679 (1995-06-01), None
patent: WO 95/18124 (1995-07-01), None
patent: WO 95/23798 (1995-09-01), None
patent: WO 02/085458 (2002-10-01), None
Navari, et al.,New England J. of Medicine, vol. 340, pp. 190-195 (1999).
Maggi et al.,J. Auton. Pharmacol., vol. 13, pp. 23-93 (1993).
Kramer et al.,Science, vol. 281, pp. 1640-1645 (1998).
Longmore et al.,Can. J. Physiol. Pharmacol., vol. 75, pp. 612-621 (1997).
Barker,Reviews in Neurosciences, vol. 7, pp. 187-214 (1996).
Quartara et al.,Neuropeptides., vol. 32(1), pp. 1-49 (1998).
Doi et al.,Eur. J. of Pharmacology., vol. 383(3), pp. 297-303 (1999).
Palma et al.,Life Sciences., vol. 67(9), pp. 985-1001 (2000).
Mutra et al.,Nature., vol. 405, pp. 180-183 (2000).
Stout et al., Neurokinin 1 Receptor Antagonists as Potential Antidepressants,Annu. Rev. Pharmacol. Toxicol.vol. 41, pp. 877-906 (2001).
Rupniak, N., Elucidating the antidepressant actions of substance P (NK1receptor) antagonists,Current Opinion in Investigational Drugs, vol. 3(2), pp. 257-261 (2002).
Humphrey, J., Medicinal Chemistry of Selective Neurokinin-1 Antagonists,Current Topics in Medicinal Chemistry, vol. 3, pp. 1423-1435 (2003).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Crystalline modifications of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline modifications of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline modifications of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3782131

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.